Full text
PDFPage 347
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brownell K. D., Stunkard A. J. The double-blind in danger: untoward consequences of informed consent. Am J Psychiatry. 1982 Nov;139(11):1487–1489. doi: 10.1176/ajp.139.11.1487. [DOI] [PubMed] [Google Scholar]
- Hill L. E., Nunn A. J., Fox W. Matching quality of agents employed in "double-blind" controlled clinical trials. Lancet. 1976 Feb 14;1(7955):352–356. doi: 10.1016/s0140-6736(76)90102-1. [DOI] [PubMed] [Google Scholar]
- Howard J., Whittemore A. S., Hoover J. J., Panos M. How blind was the patient blind in AMIS? Clin Pharmacol Ther. 1982 Nov;32(5):543–553. doi: 10.1038/clpt.1982.201. [DOI] [PubMed] [Google Scholar]
- LETEMENDIA F. J., HARRIS A. D. The influence of side-effects on the reporting of symptoms. Psychopharmacologia. 1959;1:39–47. doi: 10.1007/BF00408110. [DOI] [PubMed] [Google Scholar]
- Lewis A. Empirical or rational? The nature and basis of psychiatry. Lancet. 1967 Jul 1;2(7505):1–9. doi: 10.1016/s0140-6736(67)90055-4. [DOI] [PubMed] [Google Scholar]
- Rickels K., Lipman R. S., Fisher S., Park L. C., Uhlenhuth E. H. Is a double-blind clinical trial really double-blind? A report of doctors' medication guesses. Psychopharmacologia. 1970;16(4):329–336. doi: 10.1007/BF00404739. [DOI] [PubMed] [Google Scholar]